Navigation Links
CIMZIA(R) (Certolizumab Pegol) Provides Rapid and Sustained Relief from Signs and Symptoms of Rheumatoid Arthritis for Two Years
Date:10/27/2008

CIMZIA(R) Data Shows Long-term Improvements in Productivity, Quality of

Life and Lessened Fatigue According to Studies Presented at American

College of Rheumatology (ACR) Annual Scientific Meeting

SAN FRANCISCO, Oct. 27 /PRNewswire/ -- 5:00 AM PST -- UCB announced today results from several Phase III clinical trials evaluating CIMZIA(R) (certolizumab pegol) - the only PEGylated anti-TNF (Tumor Necrosis Factor) - presented at the American College of Rheumatology (ACR) Annual Scientific Meeting. Results from the open-label extension study to RAPID 1 met both co-primary endpoints (American College of Rheumatology (ACR) 20 response(a) scores at Week 24 and change from baseline in modified Total Sharp Scores at Week 52). Results also showed that CIMZIA together with methotrexate (MTX) provided ACR 20 response as early as Week 1 with sustained long-term benefit in relieving symptoms of rheumatoid arthritis (RA) through 100 weeks.

Another analysis investigating the rapidity of response to CIMZIA as a monotherapy (FAST 4WARD) and together with MTX (RAPID 1) was presented at the meeting. Both studies met their primary endpoints (ACR20 response rate at Week 24) with clinical and statistical significance. The analysis presented showed that the response to CIMZIA treatment was rapid in both studies with more than a third (36.7 percent) of patients receiving CIMZIA as a monotherapy (FAST 4WARD) and nearly a quarter (22.9 percent) of patients receiving CIMZIA together with MTX (RAPID 1) achieving an ACR20 response within one week, both significantly different from placebo. ACR20 response rates peaked at Week 12 in both studies and were sustained until the end of the studies (Week 24 in FAST 4WARD; Week 52 in RAPID 1).

"The data show that treatment with CIMZIA in clinical trials produced a fast and clinically meaningful effect for RA patients over an extended period of time," said Michael Schiff, M.D., study investigator and Clinical Pro
'/>"/>

SOURCE UCB
Copyright©2008 PR Newswire.
All rights reserved

7

GOOD

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine technology :

1. CIMZIA(R) (Certolizumab Pegol) Provides Long-Term Benefit Without Dose Escalation in Crohns Disease Patients
2. CIMZIA(R) (certolizumab pegol) Reduces Intestinal Lesions and Induces Endoscopic Improvement in Crohns Patients
3. Cimzia(R) Provides Long-Term Efficacy with Stable Dosing in Crohns Disease
4. CIMZIA(R) (certolizumab pegol), Significantly Reduces Structural Damage and Rheumatoid Arthritis Signs & Symptoms for Up to One Year
5. Analysis of Long-Term Vicriviroc Data Provides Evidence of Sustained Viral Suppression, Increased CD4 Cell Counts and Tolerability in Treatment-Experienced HIV-Infected Patients
6. Rubicon Provides Genome Amplification for the Cancer Genome Atlas Project
7. IDM Pharma Provides Update on Mifamurtide (L-MTP-PE) Regulatory Status Following September Meeting of European Committee for Medicinal Products for Human Use (CHMP)
8. Fralex provides update on timing of interim analysis results
9. Vanda Pharmaceuticals Provides Update on Iloperidone
10. Study Demonstrates That AHCC(R) Provides Immune Enhancement Against the West Nile Virus
11. Study Reveals Novel LCD Solution Provides Significant Benefits Versus Calcipotriol In Treatment Of Moderate Psoriasis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/17/2013)... 2013  PENTAX Medical, a healthcare industry leader ... leader in ultrasound imaging, recently announced renewed collaborative ... further innovation in the development of Endoscopic Ultrasound ... and PENTAX Medical endoscopic portfolio have formed one ... systems. This agreement will continue to grow their ...
(Date:5/17/2013)... -- Oramed Pharmaceuticals Inc. (NASDAQCM: ORMP) ( ... announced today that the United States Food and Drug ... application(IND) for ORMD-0801, its oral insulin capsule. ... to proceed," stated Nadav Kidron , ... milestone for Oramed and we look forward to continuing ...
(Date:5/16/2013)... ZURICH , May 17, 2013 ... and Research (A*STAR) and Switzerland,s Cytos ... been dosed in a Phase 1 clinical trial with their ... virus-like particle (VLP) technology. In this first Phase 1 clinical ... and its potential to protect against H1N1 influenza infection will ...
Breaking Medicine Technology:PENTAX Medical And Hitachi-Aloka Medical Continue Joint Innovation And Global Leadership In Endoscopic Ultrasound Systems 2PENTAX Medical And Hitachi-Aloka Medical Continue Joint Innovation And Global Leadership In Endoscopic Ultrasound Systems 3Oramed Receives FDA Clearance to Initiate Oral Insulin Trials in the U.S. 2Oramed Receives FDA Clearance to Initiate Oral Insulin Trials in the U.S. 3A*STAR and Cytos Bring Singapore's First Influenza Vaccine to Clinical Testing 2A*STAR and Cytos Bring Singapore's First Influenza Vaccine to Clinical Testing 3A*STAR and Cytos Bring Singapore's First Influenza Vaccine to Clinical Testing 4A*STAR and Cytos Bring Singapore's First Influenza Vaccine to Clinical Testing 5A*STAR and Cytos Bring Singapore's First Influenza Vaccine to Clinical Testing 6
... with Two Abstracts Accepted for ... November 2008, BRIDGEWATER, N.J., Sept. 4 ... the treatment of,cardiovascular and metabolic disease, today announced ... Company,s board of directors., Peter Garrambone,s career ...
... Group (NYSE: SCR ), a leading manufacturer ... the patented,anti-cancer biotech product Endu (also known as ... Phase IV clinical study., At the request ... clinical study,to further validate the safety and therapeutic ...
Cached Medicine Technology:Aegerion Pharmaceuticals, Inc. adds Peter Garrambone to Board of Directors, Secures Additional Capital for Clinical Trials 2Simcere Pharmaceutical Group Announces Interim Results of Endu Phase IV Clinical Study 2Simcere Pharmaceutical Group Announces Interim Results of Endu Phase IV Clinical Study 3
(Date:5/19/2013)... (PRWEB) May 19, 2013 Passages Malibu, ... treatment center, has announced this week the launch of ... the brands’ social media channels. “We are always ... treatment community and to get feedback regarding sobriety, what’s ... CEO and co-founder of the Passages Addiction Treatment ...
(Date:5/19/2013)... Argentina: Yoga classes ( clases de Yoga ) will ... Sivananda Yoga Vedanta Center. The center is located ... are 90 minutes and are offered all week long. ... environment, allowing visitors to enjoy the benefits of Yoga, ... , The Yoga classes follow the following principles: , ...
(Date:5/19/2013)... Ponte Vedra Beach, Florida (PRWEB) May 19, 2013 ... healthcare value and market access, is pleased to unveil ... online trade show environment that provides a powerful array ... solutions to partners in the US and abroad. , ... technology, and will offer attendees the look and feel ...
(Date:5/19/2013)... The legal team at Pulaski & ... concerted effort to connect women and families coping with ... Yaz, Yasmin & Ocella with the legal representation they ... the notorious birth control drugs as well as news ... Yaz, Yasmin & Ocella were very popular birth control ...
(Date:5/18/2013)... Cambridge House of Maryville , a BMA ... area, is hosting a Memorial Day Weekend Barbecue from 11 ... community, which is located at 6960 State Rte. 162 in ... on Medicaid, who need some help to maintain their independence. ... by homemade ice cream for dessert,” says Tracy Skaer-Henry, Administrator ...
Breaking Medicine News(10 mins):Health News:Passages Malibu Announces its Sobriety, Health, and Wellness Social Media Survey 2Health News:Passages Malibu Announces its Sobriety, Health, and Wellness Social Media Survey 3Health News:Clases de Yoga in Buenos Aires, Argentina (Yoga Classes) Now Offered by Sivananda Yoga Vedanta Center 2Health News:HealthEconomics.Com Announces HE-Xpo, a New Virtual Trade Show Devoted to Healthcare Value and Market Access 2Health News:HealthEconomics.Com Announces HE-Xpo, a New Virtual Trade Show Devoted to Healthcare Value and Market Access 3Health News:Yazsideeffects.com Connects Yaz Side Effects Sufferers With Yaz Side Effects Lawyers 2Health News:Metro East Affordable Assisted Living Community to Host Memorial Day Weekend Barbecue 2
... risk of breast cancer, most young women who were treated ... appropriate mammography screening, according to a study in the January ... chest radiation for a pediatric malignancy face a significantly increased ... of breast cancer begins to increase as early as 8 ...
... alternating cycles of chemotherapy and radiation have similar outcomes ... to data from a randomized controlled trial in the ... the National Cancer Institute. , Previous trials in ... followed by radiation was as effective as total removal ...
... Papillary Thyroid Cancer ,A germ-line mutation in the ... with multi-nodular goiter (MNG) and with progression to papillary thyroid ... have MNG progress to PTC, but a genetic link between ... to be involved in thyroid development and is expressed at ...
... HAMILTON, BERMUDA, Jan. 27 Warner Chilcott Limited (Nasdaq: ... year 2009 results.Total revenues for 2009 are expected to be ... results primarily being driven by LOESTRIN 24 FE, DORYX, and ... is anticipated to be in the range of 79% to ...
... to Protect World,s Supply of Donated Blood ... Continued Expansion into New Global Markets and ... PANTHER Instrument- Companies Also Plan Exploratory Collaboration ... Guidance Including Additional Revenue and Profit from ...
... Holmes (Amex: HH ) today announced the ... General Counsel and Corporate Secretary. He has also ... Rosenblum has over 23 years of corporate legal experience ... contract, consumer and other class actions, as well as ...
Cached Medicine News:Health News:Many women who survived childhood cancer do not undergo recommended breast cancer screening 2Health News:Sequential and alternating chemotherapy and radiation equally effective in larynx cancer therapy 2Health News:Also in the Jan. 27 JNCI 2Health News:Also in the Jan. 27 JNCI 3Health News:Also in the Jan. 27 JNCI 4Health News:Warner Chilcott Announces 2009 Financial Guidance 2Health News:Warner Chilcott Announces 2009 Financial Guidance 3Health News:Warner Chilcott Announces 2009 Financial Guidance 4Health News:Warner Chilcott Announces 2009 Financial Guidance 5Health News:Gen-Probe and Novartis Agree to Extend and Expand Blood Screening Collaboration 2Health News:Gen-Probe and Novartis Agree to Extend and Expand Blood Screening Collaboration 3Health News:Gen-Probe and Novartis Agree to Extend and Expand Blood Screening Collaboration 4Health News:Gen-Probe and Novartis Agree to Extend and Expand Blood Screening Collaboration 5Health News:Hooper Holmes Names Mark Rosenblum Senior Vice President, General Counsel and Corporate Secretary 2Health News:Hooper Holmes Names Mark Rosenblum Senior Vice President, General Counsel and Corporate Secretary 3
... reliable strength for temporary wound support. ... compliant and stretchable support material is ... is not required. Predictable absorption. Polyglactin ... inert, nonantigenic, and nonpyrogenic. ,VICRYL (polyglactin ...
Used for implantation to reinforce soft tissue. Supplied sterile in peel-open packages. Intended for one-time use....
... designed for the repair of abdominal hernias. ... has two distinct sides. One side ... layer of sodium hyaluronate and carboxymethylcellulose (similar ... coated side is bioresorbable, providing a temporary ...
... Human explant studies have confirmed Atriums ... maximum clinical performance in hernia repair. ... thinner and less dense hernia mesh ... rigid repair. Since 1994, when Atrium ...
Medicine Products: